1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > The US Blood Transfusion Diagnostics Market : Effective Strategies for Vendors to Tackle the Decrease in Blood Supply Demand


The majority of the quantitative and qualitative information contained in this research service was acquired through primary research conducted with blood banking product providers. Most consultations were conducted with vice presidents (VPs) of business units, VPs of marketing, product managers, marketing managers, marketing directors, and business development directors from various competitors in the liquid handling market. Industry-specific information obtained includes:
•Blood grouping and disease revenue breakdowns by product segments and regions
•Company revenues, market share estimates, and projected growth rates of various competitors
•Top-level customer, regional, and technology market trend information
•Market drivers, restraints, and challenges Supplementary research was conducted utilizing secondary sources including scientific journals, online media, Frost & Sullivan databases and research services, and publicly available corporate filings. Forecasts are based on the data and analyses regarding industry challenges, market drivers and restraints, and market trends. If specific revenues or market sizes were unavailable, estimates were derived through consultations with industry experts, augmented by secondary research. Growth trends specific to certain market participants are based on consultations, past growth rates, and technology reviews.

Key Findings

•The blood transfusion diagnostics market is mature, with estimated revenues of $ x million in 2014 and an expectation to reach $ x million by 2018. The growth for this period is an estimated x %.
•Approximately x % of market sales arises from the blood grouping and typing segment and x % of comes from the disease screening (serological and NAT methods) segment. NAT methods are still evolving and contribute only x % to the disease screening market.
•In the United States, this market is heavily impacted by demand for blood supply, and 2014 projected a decrease in blood supply in comparison to 2013.
•However, given that approximately x % of the sites are still using manual methods for blood typing, this market has a huge scope for automation.
•The molecular immunohematology segment is rising rapidly, particularly because hemagglutination methods are exhibiting problems. Considering the FDA has been quite slow in approving tests for IVD use, Immucor will dominate this market until its peers, such as Grifols, join the market in 2016.
•Market mergers and acquisitions (M&A) have been slow; however, 2014 was marked by Novartis’s divestiture from transfusion and transplant diagnostics. As a result, Grifols was able to strengthen its presence in Europe and other countries by adding the acquired unit from Novartis’s business unit.
•Slow improvements in new product innovation within the areas of blood typing and disease screening have led to a few interesting companies to watch. Quotient Diagnostics tops the list because of the extensive instrumentation capability to combine 3 applications into one single instrument.
•It is also important to note that more instruments are cleared for diagnostic use outside the United States. For example, Europe has more CE IVD-approved instrument assays for serological- and NAT-based methods.
•Supply chain is becoming an important component of blood banks, and several companies such as Haemonetics, Cerner, and Mediware are gaining importance. One of the persistent problems associated with automating the blood banking workflow is the interconnectivity with HIS and LIS applications.
•Adding to this problem is the FDA’s emphasis on patient safety. This has slowed down the development of blood banking software and adversely affects companies such as Mediware and Psyche Systems that are actively participating in the blood banking software market.
•CMS has increased the payment rates for certain blood services from 2013 to 2014 for services offered in a hospital outpatient setting. However, this increase in rates did not bring about any change in reimbursements for transfusion testing.
•Cost for disease screening per NAT test dropped to an average of x % from 2012 to 2013. Frost & Sullivan expects further deductions in the price per test in 2015 as a result of clinical lab fee schedule and other sequestration measures across the diagnostics industry.

Scope and Segmentation

•The market covers two segments: blood grouping and disease screening.
•The market includes only those platforms and reagents used in blood donor centers and those that are used to pre-test the quality of blood right before transfusion from the donor.
•The market includes both automated and manual methods of testing.
•Blood grouping includes instruments and reagents used for Abo and Rh testing, RBC antigen, and antibody identification and detection.
•Disease screening includes serological detection and molecular methods of detection and assays.

Market Segmentation

The study accounts for ELISA, CLIA, and other immunoassay platforms for the donor blood transfusion diagnostics market. The scope also includes both manual and automated platforms and reagents. It is important that donor screening should not be confused with patient testing. In this study, research is focused on platforms and assays that are approved for donor testing only. For donor screening and testing the research covers only kits and platforms that can detect the following diseases in donor blood.
•Serological tests: HBsAg, TPHA, Anti-HIV1/2, Anti-CMV, Anti HBc
•NAT: HIV, HCV, HBV, HAV, Parvovirus B19
•Each unit of blood is tested for red cell antibodies and infectious agents HIV-1, HIV-2, HTLV1/II, hepatitis C/B virus, West Nile virus, syphilis, and Chagas disease.

Key Questions This Study Will Answer

How is innovation changing the donor disease screening and blood grouping landscape?
Are the products/services offered today meeting customer needs or is additional development needed?
Will these products/services continue to exist, or will other companies acquire them?
Are the vendors in the space ready to go it alone, or do they need partnerships to take their businesses to the next level?
What was the trend in price for blood grouping and typing in 2012 and 2013? Has it increased or decreased?
What was the trends in price for disease screening tests in 2012 and 2013? Has it increased or decreased?

Table Of Contents

The US Blood Transfusion Diagnostics Market : Effective Strategies for Vendors to Tackle the Decrease in Blood Supply Demand
Executive Summary 5
Market Overview 18
• Types of Blood Bank Analyzers 20
• Comparison of Immunohematological Methods 23
• Voice of Customer—Factors Governing Equipment Purchase for a Transfusion Laboratory 24
• Voice of Customer 25
• Market Segmentation 26
Competitive Playbook 29
• New Market Opportunities 30
• Game-changing Strategies 31
Drivers and Restraints—Total Blood Transfusion Diagnostics Market 32
Forecasts and Trends—Total Blood Transfusion Diagnostics Market 36
• Revenue Forecast 40
Blood Grouping Segment Analysis 42
• Revenue Forecast 43
• Test Volume and Pricing Analysis for Blood Grouping Tests 48
Disease Screening Segment Analysis 51
• Revenue Forecast 52
• Test Volume and Pricing Analysis for Disease Screening and NAT Tests 56
Accredited Transfusion Centers 61
Overview of Blood Banking Supply Chain 68
Competitive Environment 72
• Market Share 73
• Product Analysis Blood Grouping 75
Company Profiles 83
Key Companies to Watch 88
• Quotient Limited 89
• Immucor 90
• Diagast 91
• 3Ti 92
The Last Word 93
Appendix 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

  • $ 9 850
  • Industry report
  • June 2016
  • by Venture Planning Group

This report provides the following data: Geographic Coverage:-          France-          Germany-          Italy-          Japan-          Spain-          ...

Blood Collection Market by Product, Application  & End User  - Forecast to 2021

Blood Collection Market by Product, Application & End User - Forecast to 2021

  • $ 5 650
  • Industry report
  • July 2016
  • by MarketsandMarkets

The blood collection market is expected reach USD 9.90 billion by 2021 from USD 7.65 billion in 2016, at CAGR of 5.3% from 2016 to 2021. Factors such as increasing number of surgical procedures requiring ...

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

  • $ 5 650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.